Business Wire

Bristol-Myers Squibb and Pfizer Present Large Real-World Observational Analysis of the Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin in Patients ...

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced findings from a real-world data analysis of the U.S. Medicare database ...
SFGate

Warfarin's Loss is Johnson & Johnson's Gain

Warfarin has long been doctor's go-to medicine for guarding against blood clots in post-operative or cardiovascular disease patients. However, an important shift that began in 2010 is having a ...
Business Wire

BMS-Pfizer Alliance to Unveil Real-World Data Analyses - Cost, Safety and Comparative Effectiveness Findings Associated with Oral Anticoagulants in Non-Valvular Atrial Fibrillation

Analyses from RWD program, ACROPOLIS, use two large U.S. databases to provide insights on Eliquis ® (apixaban), warfarin, and other direct oral anticoagulants in patients with NVAF at 2017 American ...
Healio

Eliquis linked with lower risk for post-polypectomy bleeding

Please provide your email address to receive an email when new articles are posted on . Patients who received Eliquis were at lower risk for post-polypectomy bleeding and thromboembolism than those ...
Reuters

New clot preventer works as well as warfarin with less bleeding

REUTERS - The blood clot preventer Eliquis, sold by Pfizer Inc and Bristol-Myers Squibb Co, proved as effective as widely used warfarin in treating a dangerous condition known as venous ...
Washington Examiner

Bristol-Myers, Pfizer’s Eliquis approved in Japan

TRENTON, N.J. (AP) — Regulators in Japan have approved sales of an anticlotting drug called Eliquis, developed by Bristol-Myers Squibb Co. and Pfizer Inc., that’s a potential blockbuster in a new ...